Stay updated with breaking news from Hippo Pathway. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investigators hope that first-in-class agents will combat dysfunction of the Hippo pathway, which promotes YAP and TAZ activation resulting in uncontrolled proliferation and impaired differentiation, by inhibiting the transcription function of TEAD-YAP.
/PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway,...
/PRNewswire/ -- BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecule drugs for...